Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial

BACKGROUND: Pyronaridine–artesunate is the most recently licensed artemisinin-based combination therapy. WHO has recommended that a single low dose of primaquine could be added to artemisinin-based combination therapies to reduce Plasmodium falciparum transmission in areas aiming for elimination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stone, William, Mahamar, Almahamoudou, Sanogo, Koualy, Sinaba, Youssouf, Niambele, Sidi M, Sacko, Adama, Keita, Sekouba, Youssouf, Ahamadou, Diallo, Makonon, Soumare, Harouna M, Kaur, Harparkash, Lanke, Kjerstin, ter Heine, Rob, Bradley, John, Issiaka, Djibrilla, Diawara, Halimatou, Traore, Sekou F, Bousema, Teun, Drakeley, Chris, Dicko, Alassane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721154/
https://www.ncbi.nlm.nih.gov/pubmed/35028628
http://dx.doi.org/10.1016/S2666-5247(21)00192-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721154/
https://www.ncbi.nlm.nih.gov/pubmed/35028628
http://dx.doi.org/10.1016/S2666-5247(21)00192-0

Ejemplares similares